Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Trial Profile

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Leronlimab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 27 Sep 2019 According to a CytoDyn media release, first patient has been treated in the study, under the care of Dr. Jacob Lalezari, a scientific advisor to CytoDyn and current Chief Executive Officer of Quest Clinical Research.
    • 09 Sep 2019 According to a CytoDyn media release, this trial is under the supervision of Massimo Cristofanilli, M.D., professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine.
    • 05 Aug 2019 According to a CytoDyn media release, the company has received clearance to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top